Tradestie Institutional Equity Comparison Engine · Market Close Nov 20, 2026

AVR vs EKSO: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

EKSO Wins Head-to-Head Institutional Verdict (3–2 across 6 Pillars · 4–4 Matrix Metrics)

EKSO Overall Winner 6-Pillar Tally: AVR 2 – 3 EKSO (1 Tie) Matrix Metrics: AVR 4 – 4 EKSO

As of Nov 20, 2026, Ekso Bionics Holdings, Inc. (EKSO) is the stronger overall head-to-head candidate over Anteris Technologies Global Corp. (AVR) in the Tradestie Institutional Equity Comparison Engine, winning 4–4 core matrix metrics and 3–2 across our 6-pillar institutional scorecard (led by Valuation Multiples, Balance Sheet & Cash Flow, Options & Positioning). AVR carries a Unified Composite Score of 42.0/100 (HOLD) at $4.99 (N/M Forward P/E, -4880.4% operating margin), whereas EKSO carries 58.1/100 (HOLD) at $11.80 (N/M Forward P/E, -119.7% operating margin).

  • Growth vs. Quality Trade-Off: EKSO earns the overall head-to-head edge with a stronger Unified Composite Score (58.1/100 HOLD vs. AVR 42.0/100 HOLD) and 2.16β · 76% Vol risk profile, whereas AVR leads top-line expansion (+21.0% YoY revenue growth, N/M PEG, and 2 of 6 institutional pillars) for higher-beta growth mandates.
  • Technical & Structure Timing Caution: AVR is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 34.4); meanwhile EKSO trades in a Markup technical trend (UNCLASSIFIED options phase, RSI 60.4). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About AVR vs EKSO
AVR NASDAQ
Anteris Technologies Global Corp. Common Stock
Orthopedic, Prosthetic & Surgical Appliances & Supplies
$4.99
-1.96% 1D
Market Cap $496.2M
TTM Revenue $2.3M
Forward P/E N/M
Beta / 30D Vol 1.49β · 78% Vol
Unified Composite Score
42.0 / 100 HOLD
Tech 32.0 Fund 52.0 Flow 57.0 Mom 64.0
Weinstein Technical Phase Markdown · Sell / avoid
Price below a falling SMA50 (slope -16.0%), weak momentum, RSI 34
RSI-14: 34.4 · SMA20: $5.75 · SMA50: $6.63
EKSO NASDAQ Head-to-Head Winner
Ekso Bionics Holdings, Inc. Common Stock
General Industrial Machinery & Equipment, Nec
$11.80
+0.08% 1D
Market Cap $42.0M
TTM Revenue $13M
Forward P/E N/M
Beta / 30D Vol 2.16β · 76% Vol
Unified Composite Score
58.1 / 100 HOLD
Tech 60.0 Fund 54.0 Flow 50.0 Mom 50.0
Weinstein Technical Phase Markup · Hold / add on dips
Price above SMA50, rising 50-day trend (3.2% over 20 days), RSI 60
RSI-14: 60.4 · SMA20: $10.56 · SMA50: $10.65

6-Pillar Scorecard Institutional Category Breakdown (AVR 2 – 3 EKSO)

Columns: Metric · AVR · EKSO
1. Valuation Multiples EKSO
Forward P/E N/M N/M
Trailing P/E N/M N/M
PEG Ratio N/M N/M
EV / Revenue 120.1x 3.3x
2. Growth & Scale AVR
Revenue Growth (YoY) +21.0% -38.3%
Earnings Growth (YoY) +0.0% +0.0%
TTM Revenue (USD) $2.3M $13M
Market Cap $496.2M $42.0M
3. Profitability & Quality AVR
Gross Margin 75.8% 53.5%
Operating Margin -4880.4% -119.7%
Net Profit Margin 0.0% -91.4%
Return on Equity (ROE) -93.3% -107.6%
4. Balance Sheet & Cash Flow EKSO
Cash Generation (TTM) -$94M -$11M EBITDA
Cash Flow Margin N/A -86.0% EBITDA Mgn
Net Cash / Leverage $216M Net Cash $2.54 Book/Sh · -107.6% ROE
Dividend Yield None (0.00%) None (0.00%)
5. Options & Positioning EKSO
Options Structure Phase BREAKDOWN UNCLASSIFIED
Current IV / %ile 151.1% (69th %ile) N/A (N/A)
Put/Call OI Skew 4.63x (Put-Skewed) N/A
OBV Trend / Tech Phase DISTRIBUTION · Markdown NEUTRAL · Markup
6. R&D & Supply-Chain Moat Tie
OpEx & R&D Intensity N/A N/A
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Cyclical / Execution-Driven Positioning Cyclical / Execution-Driven Positioning
Supply-Chain Role Medical Devices Operator Medical Instruments & Supplies Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: AVR (4) vs EKSO (4)
Institutional Metric AVR EKSO Criterion Row Edge
Market Capitalization
Scale
$496.2M $42.0M Larger Scale AVR
Trailing P/E Ratio
Valuation
N/M N/M Lower Multiple Tie
Forward P/E Ratio
Valuation
N/M N/M Lower Multiple Tie
Revenue Growth (YoY)
Growth
+21.0% -38.3% Higher Growth AVR
Operating Margin (TTM)
Profitability
-4880.4% -119.7% Higher Margin EKSO
Net Profit Margin
Profitability
0.0% -91.4% Higher Margin AVR
Return on Equity (ROE)
Capital Efficiency
-93.3% -107.6% Higher ROE AVR
52-Week Range Position
Momentum
22% ($3–$11) 87% ($0–$14) Stronger Trend EKSO
Beta / 30D Volatility
Risk Regime
1.49β · 78% Vol 2.16β · 76% Vol Lower Realized Risk EKSO
Unified Institutional Score
Composite Signal
42.0 / 100 (HOLD) 58.1 / 100 (HOLD) Higher Composite EKSO
Trailing 12M Revenue (USD)
Operating Scale
$2.3M $13M FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
75.8% 53.5% Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
N/M PEG · 120.1x EV/Rev N/M PEG · 3.3x EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
-$94M ($216M Net Cash) -$11M EBITDA ($2.54 Book/Sh · -107.6% ROE) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon EKSO +14.08 pp
AVR: +11.45% · EKSO: +25.53%
3M Horizon EKSO +26.26 pp
AVR: -0.33% · EKSO: +25.93%
6M Horizon EKSO +112.51 pp
AVR: +80.29% · EKSO: +192.8%
1Y Horizon EKSO +112.51 pp
AVR: +80.29% · EKSO: +192.8%

Financial Trajectory Operating Profitability Benchmark (Trailing 12-Month)

Split-Invariant USD Revenue & Operating Margin (%)

Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on AVR vs EKSO. Trailing 12-month operating profitability (AVR -4880.4% vs EKSO -119.7%) and valuation multiples (AVR N/M vs EKSO N/M Forward P/E) are benchmarked directly in Pillar 4 below.

AVR ADR TTM Benchmark FX-Normalized USD
TTM Revenue$2.3M
Gross Margin75.8%
Op. Margin-4880.4%
ROE / Fwd P/E-93.3% · N/M
EKSO ADR TTM Benchmark FX-Normalized USD
TTM Revenue$13M
Gross Margin53.5%
Op. Margin-119.7%
ROE / Fwd P/E-107.6% · N/M

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
AVR BREAKDOWN
105d in phase · OBV DISTRIBUTION
Current IV 151.1%
IV Percentile 69th %ile
Put/Call OI Skew 4.63x (Put-Skewed)
IV Regime Elevated (60th–80th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal BEARISH
OBV Flow DISTRIBUTION
Exact AVR Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
EKSO UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV N/A
IV Percentile N/A
Put/Call OI Skew N/A
IV Regime Unclassified
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact EKSO Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
AVR Moat Profile Cyclical / Execution-Driven Positioning
Medical Devices Operator
Competes within the Medical Devices value chain with $496.2M market capitalization and -4880.4% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published
EKSO Moat Profile Cyclical / Execution-Driven Positioning
Medical Instruments & Supplies Operator
Competes within the Medical Instruments & Supplies value chain with $42.0M market capitalization and -119.7% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published

Investor FAQ AVR vs EKSO Key Questions & Quantitative Answers

As of Nov 20, 2026, Ekso Bionics Holdings, Inc. (EKSO) is the stronger overall head-to-head candidate over Anteris Technologies Global Corp. (AVR) in the Tradestie Institutional Equity Comparison Engine, winning 4–4 core matrix metrics and 3–2 across our 6-pillar institutional scorecard (led by Valuation Multiples, Balance Sheet & Cash Flow, Options & Positioning). AVR carries a Unified Composite Score of 42.0/100 (HOLD) at $4.99 (N/M Forward P/E, -4880.4% operating margin), whereas EKSO carries 58.1/100 (HOLD) at $11.80 (N/M Forward P/E, -119.7% operating margin). Growth vs. Quality Trade-Off: EKSO earns the overall head-to-head edge with a stronger Unified Composite Score (58.1/100 HOLD vs. AVR 42.0/100 HOLD) and 2.16β · 76% Vol risk profile, whereas AVR leads top-line expansion (+21.0% YoY revenue growth, N/M PEG, and 2 of 6 institutional pillars) for higher-beta growth mandates. Technical & Structure Timing Caution: AVR is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 34.4); meanwhile EKSO trades in a Markup technical trend (UNCLASSIFIED options phase, RSI 60.4). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

AVR leads the Growth & Scale pillar: AVR posts +21.0% YoY revenue growth and +0.0% YoY earnings growth on $2.3M TTM revenue (75.8% gross margin, -4880.4% operating margin), compared with EKSO at -38.3% YoY revenue growth and +0.0% YoY earnings growth on $13M TTM revenue (53.5% gross margin, -119.7% operating margin). On trailing 12-month operating scale, AVR generates $2.3M in USD-normalized revenue versus $13M for EKSO. In operating R&D and SG&A reinvestment, AVR deploys N/A (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for EKSO.

EKSO screens cheaper on headline valuation multiples. AVR trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and 120.1x EV/Revenue (unreported FCF margin), whereas EKSO trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and 3.3x EV/Revenue (-86.0% EBITDA margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against AVR (-93.3% ROE) versus EKSO (-107.6% ROE) capital efficiency.

In options market volatility and institutional positioning, AVR carries 151.1% implied volatility (69th %ile, Elevated (60th–80th %ile)), a 4.63x (Put-Skewed) Put/Call open-interest ratio, DISTRIBUTION on-balance volume, and sits in a BREAKDOWN options structure phase (1.49β · 78% Vol realized risk). By comparison, EKSO carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (2.16β · 76% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 20, 2026. For educational research only; not investment advice.